A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
Financial Summary
| Share Statistics | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $18.2 | $242.6 | 10% |
|
| Shares Out (Mil) | 5.4 | 54.0 | 15% |
|
| Institutional Ownership | 98.4% | 93.1% | 78% |
|
| Float (Mil) | 5.4 | 41.4 | 13% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 11 | 633 | 18% |
|
| Price Change (52-week) |
(81.7%) | 50.0% | 8% |
|
| Growth | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.4% | 12.5% | 63% |
|
| Net Income (5yr) | (15.7%) | (10.1%) | 25% |
|
| EPS (5yr) | (228.5%) | 15.8% | 0 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 111.5% | (15.7%) | 99% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | na | ($2.430) | ($2.460) | |
| Month Ago EPS | na | ($2.430) | ($2.460) | |
| # Rev Up | na | 0 | 0 | |
| # Rev Down | na | 1 | 1 | |
| Three Months Ago EPS | na | ($2.430) | ($2.460) | |
| Year/Year Chg | na | (20.6%) | na | |
| Financials | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($14) | ($44) | 27% |
|
| EPS (TTM) | ($3.060) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($34) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $0 | $177 | 4% |
|
| Valuation | NEUP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.74 | 2.33 | 15% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.3% | 96% |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (47.0%) | (47.6%) | 12% |
|
| ROE | (61.7%) | (54.9%) | 13% |
|
| Liabilities to Assets | 14.3% | 29.3% | 9% |
|
| F-Score | 2 | 3 | na |
|
Neuphoria Therapeutics Inc. did not pass any screens on 10/9/2026.
